secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001477932-24-007203
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months
-------------------------------------------------------------------------------

- Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.
- Nu.Q Vet revenue up 307% in Q3; >110,000 tests sold in first 9 months of 2024.
- Cash used in operations $5.4M in Q3, down 36% YoY; cash balance $5.4M at Sept 30.
- Received >$2.2M in non-dilutive funding commitment from Walloon Region post-quarter.
- Reaffirms goal to be cash neutral (income matching expenditure) in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224007203/0001477932-24-007203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224007203/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-007203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer